Medtronic plans to acquire Contego Medical in a transaction valued at $380 million. The deal expands Medtronic’s portfolio of carotid technologies and includes Contego’s recently FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices.
The Neuroguard IEP Direct System is the first and only transcarotid artery revascularization system with integrated embolic protection in addition to flow reversal, according to a Nov. 16 news release. In the PERFORMANCE III study, the system recorded no strokes, neurological deaths, cranial nerve injuries or myocardial infarctions at 30 days, according to the company.
Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
